

Discipline **MCP5876** 
Critical Analysis of Heart Transplantation Results in the Treatment of Refractory Heart Failure

Concentration area: 5131

Creation: 13/12/2016

Activation: 13/12/2016

Credits: 2

Workload:

Theory (weekly)	Practice (weekly)	Study (weekly)	Duration	Total
4	12	14	1 weeks	30 hours

Professors:

Fernando Bacal

Fabiana Goulart Marcondes Braga

Sandrigo Mangini

Objectives:

Training and improvement of human resource in research and teaching in heart transplantation, emphasizing aspects related to organ donation, the patient with refractory heart failure and the results of heart transplantation. Core Question: Is heart transplantation still the best option for the treatment of refractory heart failure in Brazil and worldwide?

Rationale:

Despite the great advance in the treatment of heart failure in the last decades, this clinical syndrome still presents a high mortality rate. Heart transplantation is considered the gold standard treatment of refractory heart failure, however, situations such as the shortage of donors limit the number of transplants and combined to the severity of the recipients, it has been increasing the indication and use of ventricular assist devices. Considering a reduced population for large randomized clinical trials, the critical analysis of the available data and the proposal of new research gives insights and allows better results in the field of heart transplantation.

Content:

The course will be divided into 3 modules and the students allocated in each of them: donor, recipient and transplant. On the morning of the first day, introductory lectures will be held and after the students will have 3 periods of study to prepare the seminars and a specific task for each module. At the end there will be evaluation. Monday morning – 8-12 am (4h) Course presentation Lectures: Situation of heart transplantation in Brazil and worldwide Strategies for preservation of donated heart Strategies for indication and use of ventricular assist devices Early and late complications of heart transplantation MODULE 1 Donor – Thursday morning – 8-12 am (4h) Seminars: 40 min each Critical analysis of the functioning of the OPOs / Transplants' Center Critical analysis of donor care Critical analysis of donor

assessment risk scores Group task: Ideal model proposition to increase the number of viable donors - 30 minutes Receptor - Thursday afternoon - 1-5 pm (4h) Seminars: 40 min each Critical analysis of transplant indications (INTERMACS classification and available prognostic scores) Receptor: priority vs outpatient Critical analysis of the use of ventricular assist devices in Brazil Group task: strategies propositions to increase the number of transplants with better results in Brazil - 30 minutes MODULE 3 Transplantation - Friday morning - 8-12 am (4h) Seminars: 40 min each Critical analysis of the results of immunosuppressive therapy in heart transplantation in relation to cell-mediated and antibody-mediated rejection Infection and heart transplantation: critical analysis of heart transplantation in Chagas' disease and prevention of cytomegalovirus infection (prophylaxis vs. preemptive treatment) Critical analysis of the results of randomized studies for the treatment of cardiac allograft vasculopathy Group task: strategies propositions to improve the late results of heart transplantation - 30 minutes

Type of Assessment:

See observation field

Notes/Remarks:

EVALUATION CRITERIA: Performance in preparing and presentation of seminars and group tasks Answer to the central question of the course A study proposal involving heart transplantation and / or refractory heart failure OBSERVATION: Minimum number of students: 9 Maximum number of students: 18

Bibliography:

Weiss ES, Allen JG, Kilic A, Russell SD, Baumgartner WA, Conte JV, Shah AS. Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation. *J Heart Lung Transplant.* 2012 ; 31(3):266-73.

Smits JM, Pauw M, de Vries E, Rahmel A, Meiser B, et al. Donor scoring system for heart transplantation and the impact on patient survival. *J Heart Lung Transplant.* 2012; 31(4):387-97.

Frontera JA1, Kalb T. How I manage the adult potential organ donor: donation after neurological death (part 1). *Neurocrit Care.* 2010; 12(1):103-10.

Frontera JA. How I manage the adult potential organ donor: donation after cardiac death (part 2). *Neurocrit Care.* 2010;12(1):111-6.

Quader MA, Wolfe LG, Kasirajan V. Heart transplantation outcomes from cardiac arrest-resuscitated donors. *J Heart Lung Transplant.* 2013; 32(11):1090-5.

Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation.* 2006;113(11):1424-33.

Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). *J Heart Lung Transplant.* 2011; 30(11):1236-43.

Zugck C, Krüger C, Kell R, Körber S, Schellberg D, Kübler W, Haass M. Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model. *Eur J Heart Fail.* 2001; 3(5):577-85.

Smits JM, de Vries E, De Pauw M, Zuckermann A, Rahmel A, Meiser B, Laufer G, Reichenspurner H, Strueber M. Is it time for a cardiac allocation score? First results from the Eurotransplant pilot study on a survival benefit-based heart allocation. *J Heart Lung Transplant.* 2013; 32(9):873-80.

Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. *J Heart Lung Transplant*. 2009; 28(8):827-33.

Kirklin JK, Cantor R, Mohacsi P, Gummert J, De By T, Hannan MM, Kormos RL, Schueler S, Lund LH, Nakatani T, Taylor R, Lannon J. First Annual IMACS Report: A global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. *J Heart Lung Transplant*. 2016; 35(4):407-12.

Wever-Pinzon O, Drakos SG, Kfoury AG, Nativi JN, Gilbert EM, Everitt M, Alharethi R, Brunisholz K, Bader FM, Li DY, Selzman CH, Stehlik J. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? *Circulation*. 2013; 127(4):452-62.

Galantier J, Moreira LF, Benício A, Leirner AA, Cestari I, Bocchi EA, Bacal F, Stolf NA. Hemodynamic performance and inflammatory response during the use of VAD-InCor as a bridge to transplant. *Arq Bras Cardiol*. 2008; 91(5):327-34.

Arnaoutakis GJ, George TJ, Allen JG, Russell SD, Shah AS, Conte JV, Weiss ES. Institutional volume and the effect of recipient risk on short-term mortality after orthotopic heart transplant. *J Thorac Cardiovasc Surg*. 2012; 143(1):157-6.

Weiss ES, Allen JG, Arnaoutakis GJ, George TJ, Russell SD, Shah AS, Conte JV. Creation of a quantitative recipient risk index for mortality prediction after cardiac transplantation (IMPACT). *Ann Thorac Surg*. 2011; 92(3):914-21.

Dardas TF, Cowger J, Koelling TM, Aaronson KD, Pagani FD. The effectiveness of United Network of Organ Sharing status 2 transplantation in the modern era. *J Heart Lung Transplant*. 2011; 30(10):1169-74.

The International Society of Heart and Lung Transplantation. Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* 2010; 29:914-956

Bacal F, Souza-Neto JD, Fiorelli AI, Mejia J, Marcondes-Braga FG, Mangini S, et al. II Diretriz Brasileira de Transplante Cardíaco. *Arq Bras Cardiol*. 2009; 94(1 supl.1):e16-e73.

Mangini S, Alves BR, Silvestre OM, Pires PV, Pires LJ, Curiati MN, Bacal F. *Einstein* (Sao Paulo). 2015; 13(2):310-8. Heart transplantation: review.

Ayub-Ferreira SM, Souza JD Neto, Almeida DR, Biselli B, Avila MS, Colafranceschi AS, Stefanello B, Carvalho BM, Polanczyk CA, Galantini DR, Bocchi EA, Chamlian EG, Hojaij EM, Gaiotto FA, Pinton FA, Jatene FB, Ramires F, Atik FA, Figueira F, Bacal F, Galas F, Brito FS, Conceição-Souza GE, Ribeiro G, Ja P Jr, Souza JM, Rossi JM Neto, Lima J, Mejía JC, Fernandes JR, Baumworcel L, Moura L, Hajjar LA, Beck-da-Silva L, Rohde L, Seguro L, Pinheiro ML, Park M, Fernandes MR, Montera MW, Alves M, Mrb W Jr, Hossne N, Fernandes P, Lemos P, Schneidewind RO, Uchoa RB, Honorato R, Mangini S, Falcão S, Lopes S, Strabelli T, Guimarães T, Campanili T, Issa VS. Diretriz de Assistência Circulatória Mecânica da Sociedade Brasileira de Cardiologia. *Arq Bras Cardiol*. 2016; 107(2 Suppl 2):1-33.

Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, Wang SS, Cantin B, Van Bakel A, Ewald G, Hirt S, Lehmkuhl H, Keogh A, Rinaldi M, Potena L, Zuckermann A, Dong G, Cornu-Artis C, Lopez P. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. *Am J Transplant*. 2013; 13(5):1203-16.

Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valentine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. *N Engl J Med*. 2003; 349(9):847-58.

Hirt SW, Bara C, Barten MJ, Deuse T, Doesch AO, Kaczmarek I, Schulz U, Stypmann J, Haneya A, Lehmkuhl HB. Everolimus in Heart Transplantation: An Update. *J Transplant*. 2013; 2013:683964.

Bocchi EA, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, Fernandez D, Fiorelli A, Olaya P, Vulcado N, Perrone SV. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. *Transplant Proc.* 2006; 38(3):937-42.

Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. *J Heart Lung Transplant.* 2005; 24 (4 Suppl):S196-200.

Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR. Use of rapamycin slows progression of cardiac transplantation vasculopathy. *Circulation.* 2003; 108(1):48-53.

Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. *Circulation.* 2004; 110(17):2694-700.

Ayub-Ferreira SM, Avila MS, Feitosa FS, Souza GE, Mangini S, Marcondes-Braga FG, Issa VS, Bacal F, Chizzola PR, Cruz FD, Bocchi EA. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus. *Transplant Proc.* 2010; 42(2):542-4.

Schmauss D, Weis M. Cardiac Allograft Vasculopathy : Recent Developments. *Circulation.* 2008;117:2131-2141.

Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. *N Engl J Med.* 1993; 328(3):164-70.

Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K, Steinbeck G, Seidel D, Reichart B. Simvastatin initiated early after heart transplantation: 8-year prospective experience. *Circulation.* 2003; 107(1):93-7.

Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, Milani RV, Lavie CJ. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. *J Am Coll Cardiol.* 2002; 40(9):1609-14.

Bacal F, Moreira L, Souza G, Rodrigues AC, Fiorelli A, Stolf N, et al. Dobutamine stress echocardiography predicts cardiac events or death in asymptomatic patients long-term after heart transplantation: 4-year prospective evaluation. *J Heart Lung Transplant.* 2004;23(11):1238-44.

Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant.* 2016; 35(10):1158-1169.

Opelz G, Döhler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. *Am J Transplant.* 2005;(5): 720-8.

Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer Jr RM, Smart FW, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. *J Heart Lung Transplant.* 1999;18(4):336-45.

Reichart B, Meiser B, Viganò M, Rinaldi M, Yacoub M, Banner NR, et al. European multicenter tacrolimus heart pilot study: three year follow-up. *J Heart Lung Transplant.* 2001;20(2):249-250.

Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. *Am J Transplant.* 2006;6(6):1243-45.

Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizón Del Prado JM, Pulpón LA, et al. Superior

prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. *Am J Transplant*. 2006;6(6):1387-97.

Mentz RM Jr, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US multicenter FK506 Study group. *Transplantation*. 1998;65(1):109-13.

Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al. A randomized active-controlled trial of mycophenolatemofetil in heart transplant recipients. *Transplantation*. 1998;66(4):507-15.

Hosenpud JD, Bennett LE. Mycophenolatemofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. *Transplantation*. 2001;72(10):1662-5.

Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. *Transplantation*. 2005;79(3 Suppl):S45-6.

O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the ISHLT. *J Heart Lung Transplant*. 2006;25(10):1186-91.

Eisen HJ, Kobashigawa JA, Keogh A, Bourge R, Renlund D, Mentzer R. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. *J Heart Lung Transplant*. 2005;24(5):517-25.

Söderlund C, Rådegran G. Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression. *Transplant Rev (Orlando)*. 2015; 29(3):181-9.

Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, Kobashigawa JA, Lindenfeld J, Masri SC, Miller D, O'Connell J, Rodriguez ER, Rosengard B, Self S, White-Williams C, Zeevi A. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. *Circulation*. 2015; 131(18):1608-39.

Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. *J Heart Lung Transplant*. 2009;28(5):417-22.

Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. *J Heart Lung Transplant*. 2009;28(8):781-4.

Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant*. 2012;31(1):46-51.

Bacal F, Silva CP, Pires PV, Mangini S, Fiorelli AI, Stolf NG, Bocchi EA. Transplantation for Chagas disease: an overview of immunosuppression and reactivation in the last two decades. *Clin Transplant* 2010; 24: E29-E34.

Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by *Trypanosoma cruzi*. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. *Ann Thorac Surg*. 2001; 71(6):1833-8.

Bacal F, Silva CP, Pires PV, Moreira L. F. P., ISSA, V. S., Moreira SA, Cruz, Fatima das Dores, Strabelli T, Stolf NAG, Bocchi, EA, Ramires, JAF. Mycophenolate mofetil increased chagas disease reactivation in heart transplanted patients: comparison between two different protocols.. *American Journal of Transplantation*. , v.5, p.2017 - 2021, 2005.

Bocchi EA, Higuchi ML, Vieira MC, Stolf N, Bellotti G, Fiorelli A, Uip D, Jatene A, Pileggi F.

Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' s heart disease. *J Heart Lung Transplantation* 1998;17:399-405.

Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Bocchi EA, Stolf NA. Risk factors for Chagas' disease reactivation after heart transplantation. *J Heart Lung Transplant.* 2008;27(6):597-602. Epub 2008 Apr 24.

Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S; BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. *N Engl J Med.* 2015; 373(14):1295-306.

Kotton CN. CMV: Prevention, Diagnosis and Therapy. *Am J Transplant.* 2013; 13 Suppl 3:24-40.

Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. *Transplantation.* 2013; 96(4):333-60.

Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. *Curr Infect Dis Rep.* 2012 ; 14(6):633-41.

Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Perálvarez M, Rolando N, Harber M, Jones G, O'Riordan A, Burroughs AK, Thorburn D, O'Beirne J, Milne RS, Emery VC, Griffiths PD. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. *Am J Transplant.* 2012 ; 12(9):2457-64.

Languages taught:

Portuguese